Rezolute(US:RZLT) TMX Newsfile·2026-01-13 22:10Core Viewpoint - Rezolute, Inc. is facing potential legal claims following a significant drop in its stock price due to disappointing results from its Phase 3 clinical trial for its lead drug candidate, ersodetug [5]. Group 1: Company Overview - Rezolute, Inc. is publicly traded on NASDAQ under the ticker symbol RZLT [2]. - The company is focused on developing treatments for congenital hyperinsulinism [5]. Group 2: Clinical Trial Results - The Phase 3 sunRIZE clinical trial for ersodetug did not meet its primary and key secondary endpoints [5]. - The highest dose in the trial showed reductions in hypoglycemia events that were not statistically significant compared to placebo [5]. Group 3: Legal Implications - Faruqi & Faruqi, LLP is investigating potential claims against Rezolute for investors who suffered significant losses [2][4]. - The law firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4].